SJEPD001541_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.971823789
- umap2_2d
- 0.163607109
- umap1_3d
- 1.237357229
- umap2_3d
- 2.961441721
- umap3_3d
- -2.111945492
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.430
- INFLAMMATORY_RESPONSE+0.410
- COAGULATION+0.390
- APICAL_SURFACE+0.360
- UV_RESPONSE_UP+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- MYOGENESIS+0.330
- KRAS_SIGNALING_DN+0.320
- ANGIOGENESIS+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- MYC_TARGETS_V1-0.430
- E2F_TARGETS-0.370
- OXIDATIVE_PHOSPHORYLATION-0.370
- UV_RESPONSE_DN-0.360
- G2M_CHECKPOINT-0.350
- MITOTIC_SPINDLE-0.310
- MTORC1_SIGNALING-0.250
- ANDROGEN_RESPONSE-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.886 |
| 2 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.886 |
| 3 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.884 |
| 4 | SJEPD001519_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.868 |
| 5 | SRR1489821 | GTEX | — | 0.866 |
| 6 | SRR8613743 | — | D | 0.865 |
| 7 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.862 |
| 8 | 9075936e-cc58-4740-abf4-1c733abb3d9f | — | — | 0.861 |
| 9 | SRR3147742 | — | — | 0.861 |
| 10 | fb24d93c-9681-4d45-801f-9dcfd8c5703e | — | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |